Bio-Rad Laboratories has launched a range of recombinant monoclonal anti-ranibizumab antibodies that are highly specific for the monoclonal antibody drug or the complex of the drug with its target, vascular endothelial growth factor A (VEGF-A).
antibodies
“We are excited to introduce four anti-ranibizumab antibodies that are highly specific for ranibizumab or the ranibizumab-VEGF-A complex,” said Amanda Turner, Bio-Rad product manager, Life Science Group. “Ranibizumab is a Fab fragment drug and is present at very low levels in patient samples, which presents challenges for PK assay design and sensitivity. The high affinity ranibizumab-VEGF complex specific antibody is unique to Bio-Rad and overcomes those challenges by enabling the development of a PK antigen capture assay to measure free drug.”
Ranibizumab (Lucentis) is used for the treatment of wet age-related macular degeneration (AMD), macular oedema and diabetic retinopathy. The anti-ranibizumab antibodies are inhibitory, non-inhibitory, and drug-target complex specific antibodies and designed for use in pharmacokinetic (PK) and immunogenicity assays for ranibizumab and biosimilars.
These anti-ranibizumab antibodies are approved for in vitro research and for commercial applications of in vitro testing services that support preclinical and clinical drug and biosimilar development and patient monitoring.